Background: To identify HBV RT and HBsAg quasispecies heterogeneity in patients with acute hepatitis B (AHB) and to define their clinical value.
Methods: This study included 62 HBsAg+ and IgM/anti-HBc+ patients with clinical and biochemical signs of AHB (44 infected by genotype [gen] D and 18 by gen A) observed from 2000 to 2010. Ultra-deep sequencing (UDPS) was performed on plasma samples obtained at first observation. Drug-resistance and immune-escape mutations were retrieved from literature. Shannon Entropy (weighted for the intra-patient prevalence of each mutated position) was used to measure the extent of amino acid variability of HBsAg positions.
Results: 75.8% of patients were male with median (IQR) age of 36(29-46)years. Median (IQR) ALT and median (IQR) serum HBV-DNA were 2,544(1,938-3,078)U/L and 5.88(4.47-7.37)log10IU/ml. 61/62 became HBsAg-negative with 33/61 developing anti-HBs (marker of full immune control). By UDPS, drug resistance mutations (rtV173L/rtL180M/rtA181T/rtA194T/rtM204I) were detected in 8.1% of patients with an intra-patient prevalence ranging from 0.11% for rtA181T to 99.98% for rtL180M. UDPS also detected >1 immune-escape mutation within the a-determinant in 48.4% of patients with an intra-patient prevalence from 0.16% to 100%. Among them, vaccine-escape mutations were found only in gen D. This is the case of sG145R, sM133L, and sP120S, detected in 11.4% of patients, with an intra-patient prevalence ranging from 3.9% to 99.9% for sG145R, from 1.9% to 16.8% for sM133L, and from 100% to 100% for sP120S. Similarly, stop-codons were found in 19.3% patients (intra-patient prevalence range:1.6%-47.5%). They occurred at 11 HBsAg positions including 172 and 182 known to correlate with an increased HBV oncogenic potential. Finally, in gen D, an higher Shannon Entropy at specific HBsAg positions correlated with no anti-HBs production. Among them, positions 130 and 133 (localized in HLA class II epitope ranging aa 124-137) were found mutated only in patients not developing anti-HBs (1.98±0.011 vs 0, and 1.95±0.033 vs 0, respectively, P<0.05).
Conclusions: A substantial fraction of AHB-patients is characterized by a complex viral quasispecies with reduced antigenicity/immunogenicity, enhanced oncogenic-potential and/or altered drug-susceptibility. These viral variants may potentially expose patients to severe and/or difficult-to-treat forms of HBV-infection (also in the setting of HBV reactivation), and may affect the efficacy of current HBV vaccination strategy.